Tomoya Fukui

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Topics

Hodgkin Lymphoma

Brain Metastases

Epidermal Growth Factor Receptor

Top Venues

Thoracic cancer

Targeted oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Makoto Hibino, Yoshinori Imamura, Rai Shimoyama, Tomoya Fukui, Ryuta Fukai, Akihiko Iwase, Yukihiro Tamura, Yusuke Chihara, Takafumi Okabe, Kiyoaki Uryu, Tadahisa Okuda, Masataka Taguri, Hironobu Minami
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01. Targeted oncology (2024)
Tomoya Fukui, Jiichiro Sasaki, Satoshi Igawa, Akiko Kada, Toshiki I Saito, Yoshihito Kogure, Hiroaki Okamoto, Katsuhiko Naoki
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040). BMC cancer 22 (1) (2022)
Tomoya Fukui, Jiichiro Sasaki, Satoshi Igawa, Akiko Kada, Toshiki I Saito, Yoshihito Kogure, Hiroaki Okamoto, Katsuhiko Naoki
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040). BMC cancer 22 (1) (2022)
Tomoya Fukui, Jiichiro Sasaki, Satoshi Igawa, Akiko Kada, Toshiki I Saito, Yoshihito Kogure, Hiroaki Okamoto, Katsuhiko Naoki
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040). BMC cancer 22 (1) (2022)
Tomoya Fukui, Shinji Hosotani, Itaru Soda, Takahiro Ozawa, Seiichiro Kusuhara, Mikiko I Kakegawa, Masashi Kasajima, Yasuhiro Hiyoshi, Satoshi Igawa, Masanori Yokoba, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, Hiromichi Ishiyama, Katsuhiko Naoki
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab. Thoracic cancer 11 (4) (2020)
Tomoya Fukui, Mikiko Ishihara, Masashi Kasajima, Yasuhiro Hiyoshi, Yoshiro Nakahara, Sakiko Otani, Satoshi Igawa, Masanori Yokoba, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, Katsuhiko Naoki
Questionnaire survey on patient awareness of invasive rebiopsy in advanced non-small cell lung cancer. Thoracic cancer 10 (3) (2019)
Taihei Ono, Satoshi Igawa, Takahiro Ozawa, Masashi Kasajima, Mikiko Ishihara, Yasuhiro Hiyoshi, Seiichiro Kusuhara, Noriko Nishinarita, Tomoya Fukui, Masaru Kubota, Jiichiro Sasaki, Mitsufuji Hisashi, Masato Katagiri, Katsuhiko Naoki
Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. Thoracic cancer 10 (4) (2019)